Pharmacokinetics and Safety/Tolerability of CKD-379

• Status: Not yet recruiting
• Trial end date: 2023-04-13
• Target enrollment: 0
• Participant gender: All

Summary

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical

Criteria

Inclusion Criteria:

• Between 19 aged and 50 aged in healthy adult

• 50.0kg≤Body weight≤90.0kg and 18.0kg/m2≤body mass index(BMI)≤27.0kg/m2

Exclusion Criteria:

• Have clinical significant medical history or disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, digestive system, urinary system, endocrine system(Type I or Type II Diabetes Mellitus, diabetic ketoacidosis etc.), hematological system, cardiovascular system(heart failure, Torsades de pointes etc.), mental illness

• Have clinical significant medical history or disease that urinary tract infection or genital infection including urosepsis, pyelonephritis

• Have a gastrointestinal disease(Crohn's disease, ulcer etc.) history that can effect drug absorption or surgery

• Those who are pregnant or breastfeeding

• Those who are deemed inappropriate to participate in clinical trial by investigators